Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive
metastatic breast cancer patients after failure of trastuzumab containing regimens.